
Martin R. Sprick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2246774/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin. Cancer Discovery, 2021, 11, 638-659.	9.4	65
2	Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. Molecular Cancer Research, 2021, 19, 688-701.	3.4	22
3	Therapy resistance on the RADar in ovarian cancer. EMBO Molecular Medicine, 2021, 13, e14010.	6.9	2
4	Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. Science Translational Medicine, 2021, 13, eabe6805.	12.4	36
5	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 173, 155-165.	2.5	11
6	Single cell polarity in liquid phase facilitates tumour metastasis. Nature Communications, 2018, 9, 887.	12.8	45
7	Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1147-E1156.	7.1	128
8	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	7.0	81
9	Still a hopeless case for personalized oncology? Pancreatic cancer revisited. Oncoscience, 2018, 6, 285-286.	2.2	0
10	The linear ubiquitin chain assembly complex regulates <scp>TRAIL</scp> â€induced gene activation and cellÂdeath. EMBO Journal, 2017, 36, 1147-1166.	7.8	90
11	Martin Leverkus, 1965–2016. Cell Death Discovery, 2017, 3, 16093.	4.7	0
12	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology, 2017, 17, 629-634.	1.1	16
13	Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-IºB Activation and Cell Survival. Cell Reports, 2017, 19, 785-797.	6.4	84
14	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	12.8	131
15	Screening drug effects in patientâ€derived cancer cells links organoid responses to genome alterations. Molecular Systems Biology, 2017, 13, 955.	7.2	163
16	Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Pancreas, 2017, 46, 311-322.	1.1	22
17	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 160, 277-290.	2.5	23
18	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	4.6	75

MARTIN R. SPRICK

#	Article	IF	CITATIONS
19	The influence of prostatic anatomy and neurotrophins on basal prostate epithelial progenitor cells. Prostate, 2016, 76, 114-121.	2.3	2
20	Protein profile of basal prostate epithelial progenitor cells—stageâ€specific embryonal antigen 4 expressing cells have enhanced regenerative potential <i>in vivo</i> . Journal of Cellular and Molecular Medicine, 2016, 20, 721-730.	3.6	5
21	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	30.7	184
22	The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. Breast Cancer Research, 2015, 17, 146.	5.0	54
23	Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin. Stem Cell Reports, 2015, 4, 503-518.	4.8	24
24	A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell, 2015, 162, 146-159.	28.9	100
25	CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death and Differentiation, 2015, 22, 1192-1202.	11.2	45
26	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer, 2015, 15, 403.	2.6	70
27	Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1034-1046.	1.7	18
28	Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 678-686.	1.6	38
29	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer, 2014, 14, 512.	2.6	65
30	Development and Characteristics of Preclinical Experimental Models for the Research of Rare Neuroendocrine Bladder Cancer. Journal of Urology, 2013, 190, 2263-2270.	0.4	14
31	Label retaining cells in cancer – The dormant root of evil?. Cancer Letters, 2013, 341, 73-79.	7.2	17
32	Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene, 2013, 32, 1539-1548.	5.9	55
33	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 2013, 31, 539-544.	17.5	920
34	The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation. Cancer Research, 2010, 70, 719-729.	0.9	326
35	Potential Role of Soluble TRAIL in Epithelial Injury in Children with Severe RSV Infection. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 697-705.	2.9	38
36	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology, 2010, 138, 2357-2367.	1.3	130

MARTIN R. SPRICK

#	Article	IF	CITATIONS
37	Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 2010, 12, 468-476.	10.3	1,623
38	Correction for Vermeulen et al., Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9534-9534.	7.1	0
39	One renegade cancer stem cell?. Cell Cycle, 2009, 8, 803-808.	2.6	22
40	Tumor microvasculature supports proliferation and expansion of gliomaâ€propagating cells. International Journal of Cancer, 2009, 125, 1222-1230.	5.1	53
41	Cancer stem cells – old concepts, new insights. Cell Death and Differentiation, 2008, 15, 947-958.	11.2	320
42	Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene, 2008, 27, 3211-3220.	5.9	89
43	NF-κB Inhibition Reveals Differential Mechanisms of TNF Versus TRAIL-Induced Apoptosis Upstream or at the Level of Caspase-8 Activation Independent of cIAP2. Journal of Investigative Dermatology, 2008, 128, 1134-1147.	0.7	61
44	Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13427-13432.	7.1	654
45	Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Clinical Cancer Research, 2007, 13, 6541-6542.	7.0	8
46	Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis. Clinical Cancer Research, 2007, 13, 3403-3412.	7.0	115
47	TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 2007, 45, 649-658.	7.3	108
48	Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Therapy, 2007, 14, 316-326.	4.6	15
49	Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death and Differentiation, 2006, 13, 1740-1751.	11.2	19
50	cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-κB Activation at the Death-inducing Signaling Complex in Human Keratinocytes. Journal of Biological Chemistry, 2004, 279, 52824-52834.	3.4	46
51	Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death and Differentiation, 2004, 11, S86-S96.	11.2	178
52	The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 125-132.	4.1	178
53	TRAIL-Induced Apoptosis and Gene Induction in HaCaT Keratinocytes: Differential Contribution of TRAIL Receptors 1 and 2. Journal of Investigative Dermatology, 2003, 121, 149-155.	0.7	59
54	Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. Molecular and Cellular Biology, 2003, 23, 777-790.	2.3	109

#	Article	IF	CITATIONS
55	TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus. Journal of Immunology, 2003, 170, 1814-1821.	0.8	97
56	Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO Journal, 2002, 21, 4520-4530.	7.8	303
57	Molekulare Basis für neue therapeutische AnsÃæe. , 2002, , 27-39.		0
58	Biochemistry and function of the DISC. Trends in Biochemical Sciences, 2001, 26, 452-453.	7.5	64
59	FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2. Immunity, 2000, 12, 599-609.	14.3	748